Regulatory Affairs Outsourcing Market (2026 - 2033)

Regulatory Affairs Outsourcing Market Summary

The global regulatory affairs outsourcing market size was valued at USD 7.7 billion in 2025 and is projected to grow from USD 8.4 billion in 2026 to USD 14.6 billion in 2033, at a CAGR of 8.3% from 2026 to 2033. Asia Pacific dominated the market, accounting for a revenue share of 41.0% in 2025. Outsourcing regulatory affairs has become an increasingly important practice in the healthcare industry. A rise in geographical expansion activities by companies that aim for speedy approvals in local markets is expected to contribute to the adoption of outsourcing models for regulatory services.

The outsourcing market for regulatory affairs is expanding rapidly due to increased R&D activities, rising preference for personalized medicine and biologics, augmenting the volume of clinical trial applications and product registrations. Furthermore, healthcare companies are under constant pressure to procure timely clinical approvals from regulators in different countries. Such actions further promote the demand for regulatory affairs services, thus contributing to market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Increasing demand to obtain approval for new products while maintaining compliance, driving market progression. According to a survey sponsored by Genpact, 72.0% of executives from the life sciences industry consider regulatory compliance as one of the top three challenges life sciences companies face. Regulatory departments often face the burden of handling multiple tasks simultaneously and must ensure compliance with stringent regulatory standards. An increase in efforts by companies to expand their geographical reach and gain rapid approvals in global markets is expected to further contribute to the adoption of outsourcing

models for regulatory services. High pressure on life sciences companies to reduce development costs further propels market growth opportunities. Growing usage of generics and demand for drugs & medical devices at affordable prices is expected to reduce healthcare costs, thereby boosting preference for regulatory affairs outsourcing.

Rising out-of-pocket expenditure among developed and developing countries, uneven economic growth, and measures taken by several governments to reduce the cost of drugs are a few factors contributing to the economic and competitive pressure, which, in turn, is expected to drive the demand for regulatory affairs outsourcing among life science companies. Product-specific clinical advice & strategy, and regulatory compliance at the early stages of product development can be critical to product approval. Failure to address regulatory compliance in the early development stages often leads to delays in the approval process owing to inappropriately designed studies, manufacturing oversights, omitted studies, and other failures to meet regulatory requirements.

Globalization of biopharmaceutical and medical device companies is likely to be one of the major market drivers. Emerging markets from Asia Pacific, Latin America, and MEA regions offer low product development & manufacturing costs, tax benefits, and availability of skilled labor at relatively low costs with supportive regulations. The abovementioned factors have made the regional markets attractive prospects in terms of outsourcing and expansion for biopharmaceutical & medical device companies, thus stimulating the demand for regulatory services. Further, rising adoption of decentralized clinical trials, fast-track approvals, and global harmonization in new product development are a few other factors bolstering overall market demand.

Analyst Perspective

Growing regulatory and R&D investments continue to drive robust expansion within the global Regulatory Affairs Outsourcing Market, with both pharmaceutical and biotechnology companies opting to outsource management of complicated multi-region approvals and compliance regulations to CROs and regulatory service providers. Increasing clinical trial volumes and growing biologic and biosimilar research, as well as heightened regulatory standards imposed by bodies such as the FDA and EMA, are increasing the need for outsourced regulatory writing, submission preparation, and life cycle management support. Efforts by companies to accelerate market approval and gain faster access to global markets are likely to increase investment in such outsourced solutions. The emergence of AI-powered tools and collaborative partnerships among CROs and tech companies are changing current regulatory processes for increased efficiency and speed in submissions, but remain somewhat under pressure.

Service Insights

On the basis of service, the market is categorized into regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, regulatory submissions, regulatory operations, and others. The product registration and clinical trial applications segment dominated the market and accounted for the largest revenue share of around 24.5% of the global revenue in 2025. The increasing number of clinical trials across the globe, stringent regulations in developed markets, and legal/regulatory reforms in emerging markets such as Asia Pacific are driving the outsourcing trend for clinical trial applications.

The legal representation services segment is anticipated to witness the fastest growth rate over the forecast period. The segment growth is owing to increasing demand for legal representatives worldwide on account of the globalization of medical devices and pharmaceutical companies. The regulations are complex and ever changing. The changing regulatory landscape in regions such as Asia Pacific, MEA, and Latin America is expected to increase the demand for local experts for legal representation in obtaining regulatory approvals and customs clearance. These factors are promoting the demand for legal representation services across the world.

Company Size Insights

On the basis of company sizes, the market has been segmented into small, medium, and large. The medium-sized companies segment accounted for a share of around 45.0% in 2025 and is estimated to expand further, retaining the leading position over the forecast period. The presence of several mid-sized established providers, especially privately held ones, is anticipated to contribute to this segment share. Moreover, medium-sized pharmaceutical and medical device companies do not have enough capital to develop an in-house regulatory affairs team, which is further driving the demand for regulatory affairs outsourcing among these companies.

The large companies’ segment is projected to register a significant growth rate over the forecast period. Large companies prefer to establish long-term relations with their service providers to avoid sudden disruption in their operations and thus, prefer a service provider that can meet their regulatory needs to support their various cross-scale and ramp-up operations. According to Deloitte's Global Outsourcing Survey 2024, organizations are increasingly adopting a multidimensional sourcing model that combines outsourcing, insourcing, and digital workforces, while continuing to expand outsourcing into both traditional and core business functions. Such services allow companies to draw on specific expertise, enhance flexibility, and mitigate the challenges of fixed operational costs, which may become quite expensive in specialized and complicated regulated industries like pharmaceuticals. These factors are contributing to the growth of this segment.

Category Insights

The category segment is subdivided into drugs, biologics, and medical devices. Drugs segment dominated the market and accounted for the largest share of around 37.8% in 2023. The segment is currently leading the regulatory affairs outsourcing market due to the increasing demand for regulatory support services in the pharmaceutical industry. With the growing number of new drug applications and the increasing complexity of regulatory requirements, pharmaceutical companies are increasingly outsourcing their regulatory affairs functions to specialized service providers. Outsourcing enables these companies to access the expertise of regulatory professionals and reduce costs associated with maintaining an in-house regulatory affairs team. In addition, the pharmaceutical segment is also witnessing growth due to the increasing focus on drug safety, efficacy, and quality, which requires extensive regulatory support.

However, the medical device segment is projected to register a considerable CAGR over the forecast period, which can be attributed to the fact that medical devices companies are now focusing on their core competencies and outsourcing non-core functions to increase their productivity and operational efficiency. The growing demand for advanced medical devices and new technological advancements in medical devices are further contributing to the growth of the segment.

Indication Insights

The oncology segment dominated the market and accounted for the largest share of over 30.5% in 2025. The recent advances in the biology of cancer and the emergence of new tools for genome analysis have opened a clinical perspective in oncology, which has led to the development of personalized medicines. Scientific progress is driving an increase in the number of personalized medicine products and services, subject to regulatory review, thereby contributing to market growth.

The immunology segment is expected to expand at a significant CAGR over the forecast period. This is owing to its potential in facilitating the treatment of various cardiovascular, neurological, oncological, and inflammatory diseases. The strategic initiatives undertaken by market players in immunology are anticipated to facilitate segment growth. For instance, in April 2024, Vertex Pharmaceuticals acquired Alpine Immune Sciences to strengthen its immunology and autoimmune disease pipeline by adding novel protein-based immunotherapy candidates.

Product Stage Insights

The clinical studies segment dominated the market and accounted for the largest revenue share of around 45.0% in 2025. This can be attributed to the increasing number of clinical trial registrations over the past few years. According to ClinicalTrials.gov, more than 34,000 clinical trials were registered in 2024, compared to nearly 33,600 in 2023, showing steady growth in global clinical research activity. Moreover, this rise in the number of biologics, high demand for advanced technologies, and a requirement for personalized orphan drugs & medicines are other factors likely to fuel segment growth during the forecast period.

The preclinical segment is anticipated to expand at the fastest CAGR over the forecast period from 2026 to 2033. The rising demand for novel disease treatments, such as Zika virus and Ebola, and the increasing prevalence of existing diseases, such as CVDs, cancer, and neurological diseases, are the key factors contributing to the preclinical segment’s growth. Moreover, stringent regulations related to preclinical studies, laid down by global regulatory bodies, such as the International Conference on Harmonization (ICH), WHO, FDA, EMEA (Europe), PMDA (Japan), ANVISA (Brazil), MHRA (UK), & ROEB (Canada), are further driving the demand for regulatory affairs outsourcing agencies for preclinical studies.

End-use Insights

The pharmaceutical companies segment dominated the market and accounted for the largest share of around 38.0% in 2025. The growth in evolving areas, such as biosimilar, orphan drugs, and personalized medicines, is creating a surge in demand for regulatory services, thereby boosting the growth of this segment. In addition, a significant number of new drugs entering the pharmaceutical industry has further favored the segment growth.

The medical device and biotechnology companies segments registered substantial shares in the market in 2025. This can be attributed to the increased demand for biopharmaceuticals, vaccines, advanced medical devices, and other products. The growing demand for wearable technologies, along with recent epidemic events, is further contributing to the share of these segments in the overall market. Furthermore, the increasing number of launches pertaining to medical devices is another significant factor boosting demand for regulatory affairs services, thus supporting segmental growth.

Regional Insights

The Asia Pacific region dominated the regulatory affairs outsourcing market and accounted for the largest revenue share of approximately 41.0% in 2025. The region is also projected to witness the fastest CAGR over the forecast period. This can be attributed to the increasing number of clinical trials and the rising number of companies trying to enter markets in developing countries, such as India and China. Furthermore, the availability of a skilled workforce in the region at lower costs compared to the U.S. is another factor expected to propel the regional market growth.

To learn more about this report, Download Free Sample Report

China is one of the most attractive markets for the biopharmaceutical industry. Growing geriatric population and the presence of a large population belonging to the middle-income group are further increasing the demand for innovative and cost-effective medicines, which is expected to attract major biopharmaceutical and medical devices companies in this region. Seeking approval for new drugs is a primary challenge faced by biopharmaceutical companies, as clinical trial application process takes 12 to 24 months while approval process may require more than six years. Along with national approvals, the new drug requires approval at both provincial and city levels, which may require an additional 4 to 5 years.

Reforms in the healthcare sector in recent times are expected to streamline the approval process. Furthermore, recent pricing reforms are expected to attract multinational companies, contributing to the demand for regulatory services. For instance, in May 2024, AbbVie acquired Landos Biopharma to strengthen its immunology pipeline for inflammatory and autoimmune diseases such as ulcerative colitis and Crohn’s disease. Such initiatives are expected to propel the demand for regulatory affairs services in China.

North America Regulatory Affairs Outsourcing Market Trends

The North America regional market also reported a significant share in the global industry. The presence of key pharmaceutical and medical device companies and the rise in R&D spending in the region are some of the key factors driving the market in North America. North America and Europe are expected to be the key markets for regulatory affairs outsourcing, owing to the presence of two major international regulatory agencies, the European Medicines Agency (EMA) and the U.S. FDA, which regulate more than half of the medical devices worldwide.

U.S. Regulatory Affairs Outsourcing Market Trends

The U.S. accounted for a notable share of clinical trial applications across the globe in 2025. Along with branded and patented products, there is a strong demand for cost-effective generic and biosimilar products in this region. For instance, in 2024, the U.S. Food and Drug Administration (FDA) continued to expand approvals of biosimilar, including new oncology and autoimmune treatment options, strengthening competition in the biologics market and increasing the need for regulatory affairs support in submission, compliance, and lifecycle management.

Key Regulatory Affairs Outsourcing Market Companies Insights

The major players operating across the regulatory affairs outsourcing market are focused on the adoption of several strategic initiatives, such as mergers, partnerships, acquisitions, etc. Companies such as Labcorp Drug Development, Charles River Laboratories, ICON plc, Genpact, WuXi AppTec, and Parexel International Corporation hold a notable share of the market. This is owing to their comprehensive service portfolio, covering a wide range of regulatory affairs outsourcing services.

Moreover, these companies are continuously investing in cutting-edge technologies for regulatory affairs to offer more accurate and efficient services. This technological advantage helps attract clients and contribute to a larger market share. The multinational presence of these companies, coupled with the implementation of strategic initiatives such as partnerships, mergers & acquisitions, contributes to the company’s market presence.

Key Regulatory Affairs Outsourcing Companies

The following are the leading companies in the regulatory affairs outsourcing market. Financials, strategy maps & products of these regulatory affairs outsourcing companies are analyzed to map the supply network.

• Genpact

• WuXi AppTec

• Medpace

• Charles River Laboratories

• ICON plc

• Labcorp.

• Parexel International (MA) Corporation.

• Freyr

• PHARMALEX GmbH

• NDA Group

• APCER Life Sciences, Inc.

• tranScrip

• VCLS

• PrimeVigilance Ltd

• ProPharma Group MIS Limited

• Excelya

• BioMapas

Recent Developments

• In September 2025, Parexel announced a strategic partnership with AI company Weave Bio to accelerate regulatory submission processes using AI-enabled regulatory writing and IND preparation tools, aimed at reducing submission timelines while maintaining FDA/EMA compliance standards.

• In June 2025, The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) strengthened its “fast, expert and open” regulatory strategy to accelerate approvals and improve global collaboration, promoting risk-proportionate regulation and increasing the need for regulatory consulting and submission expertise from CROs and outsourcing partners.

• In July 2025, Parexel expanded its regulatory consulting leadership by appointing former FDA experts to strengthen regulatory oncology, AI policy, and global submission capabilities, reflecting growing complexity in regulatory compliance and increasing outsourcing demand from pharma sponsors.

Global Regulatory Affairs Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global regulatory affairs outsourcing market report based on services, company size, category, indication, stage, end use, and region:

• Service Outlook (Revenue, USD Billion, 2021 - 2033)

  • Regulatory Consulting

    • Strategy & Development Planning

    • QA Consulting

    • Others

  • Legal Representation

  • Regulatory Writing & Publishing

  • Product Registration & Clinical Trial Applications

  • Regulatory Submission

  • Regulatory Operations

  • Other Services

• Company Size Outlook (Revenue, USD Billion, 2021 - 2033)

  • Small

  • Medium

  • Large

• Category Outlook (Revenue, USD Billion, 2021 - 2033)

  • Pharmaceuticals

    • Regulatory Consulting

      • Strategy & Development Planning

      • QA consulting

      • Others

    • Legal Representation

    • Regulatory Writing & Publishing

    • Product Registration & Clinical Trial Applications

    • Regulatory Submissions

    • Regulatory Operations

    • Other Services

  • Medical Device

    • Regulatory Consulting

      • Strategy & Development Planning

      • QA Consulting

      • Others

    • Legal Representation

    • Regulatory Writing & Publishing

    • Product Registration & Clinical Trial Applications

    • Regulatory Submissions

    • Regulatory Operations

    • Other Services

• Indication Outlook (Revenue, USD Billion, 2021 - 2033)

  • Oncology

  • Neurology

  • Cardiology

  • Immunology

  • Others

• Product Stage Outlook (Revenue, USD Billion, 2021 - 2033)

  • Preclinical

  • Clinical

  • PMA (Post Market Authorization)

• End-use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Medical Device Companies

  • Pharmaceutical Companies

  • Biotechnology Companies

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.                    

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Russia

    • Turkey

    • Netherlands

    • Switzerland

    • Sweden

    • Europe CIS Countries

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Indonesia

    • Malaysia

    • Singapore

    • Thailand

    • Taiwan

    • CIS Countries

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

    • Chile

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Egypt

    • Israel

    • Kuwait